CORDIS · 777357 · H2020
RTCure Rheuma Tolerance for Cure
Coordinator: KAROLINSKA INSTITUTET (SE)
In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progression by inhibiting maturation/expansion of pathogenic autoimmune responses through immune tolerising treatments of subjects not only in earlystages of joint inflammation (undifferentiated arthritis and early RA) but also in even earlier defined stages i.e. before onset of joint inflammation, when patients have arthralgia and/or bone loss, or sub-clinical stages of joint inflammation.Today, no drugs are approved for these early phases of RA development, where…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €6.0M awarded to the consortium. The project runs over approximately 6 years from 2017-09-01 to 2023-08-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from SE
see all →- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · FP7 · €109.4M
- GrapheneCore1 — Graphene-based disruptive technologies696656 · H2020 · €89.0M
- GrapheneCore2 — Graphene Flagship Core Project 2785219 · H2020 · €88.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · FP7 · €75.3M
- 2D-EPL — Graphene Flagship 2D Experimental Pilot Line952792 · H2020 · €20.0M
- BrightnESS — Building a research infrastructure and synergies for highest scientific impact on ESS676548 · H2020 · €19.9M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-JTI-IMI2-2016-09-two-stage.
- Who coordinates the project?
- The project is coordinated by KAROLINSKA INSTITUTET (SE).
- What is the project timeline?
- The project runs from 2017-09-01 to 2023-08-31 — approximately 6 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 777357.